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At the endothelial cell surface, binding of chylomicrons and lipoprotein lipase (LpL), the major
enzyme involved in the processing of these triglyceride-rich lipoproteins, is thought to involve
electrostatic interactions with glycosaminoglycans. A new study published in this issue of Cell
Metabolism (Beigneux et al., 2007) provides evidence for a specific chylomicron/LpL receptor, which
may serve as a platform for LpL-mediated processing of chylomicrons on the capillary endothelium.Chylomicrons are triglyceride-rich
lipoproteins that are synthesized by
the intestinal epithelium and deliver di-
etary lipids to peripheral tissues. In the
bloodstream, triglycerides transported
by chylomicrons undergo lipolysis
through the action of lipoprotein lipase
(LpL) at the surface of the capillary en-
dothelium, liberating free fatty acids
for uptake by tissues. It is thought
that LpL, which is synthesized by non-
endothelial parenchymal cells, is teth-
ered to the endothelial cell surface
through electrostatic interactions be-
tween the positively charged heparin-
binding domains of LpL and negatively
charged glycosaminoglycans (GAGs),
such as heparan sulfate proteoglycans
(HSPGs) (Goldberg, 1996). Non-HSPG-
binding proteins have been proposed
to mediate association of LpL to the
cell surface, similar to that observed
for some apolipoproteins and growth
factors. However, the molecular basis
of the LpL-chylomicron interaction is
poorly understood.
In this issue, Beigneux et al. (2007)
report on the identification of an endo-
thelium-expressed protein, glycosyl-
phosphatidylinositol-anchored high-
density lipoprotein-binding protein 1
(GPIHBP1), which is required for the
lipolytic processing of chylomicrons.
GPIHBP1 was previously identified as
a GPI-linked protein that facilitated
the binding of high-density lipopro-
teins to cultured cells (Ioka et al.,
2003). To examine the role of
GPIHBP1 in lipoprotein metabolism,Beigneux and colleagues generated
Gpihbp1/ mice by gene targeting.
Surprisingly, these mice developed
milky plasma with markedly elevated
plasma triglycerides, the vast majority
of which were associated with the chy-
lomicron/VLDL fraction. The authors
demonstrate that GPIHBP1 is highly
expressed in the same tissues that
express LpL (i.e., heart and adipose
tissue) and localizes to the luminal
face of the capillary endothelium.
Moreover, Beigneux and colleagues
convincingly show that expression of
GPIHBP1 confers upon cultured cells
the ability to bind LpL and chylomi-
crons, prompting them to propose
a role for GPIHBP1 as a molecular
platform for LpL-mediated processing
of chylomicrons on the capillary endo-
thelium.
How might GPIHBP1 mediate LpL
and chylomicron binding? GPIHBP1
harbors a strongly acidic negatively
charged domain that could potentially
bind to the positively charged domains
of apolipoproteins (e.g., apo-B48,
apo-E, and apo-AV) contained in chy-
lomicrons (Figure 1A). Likewise, the
acidic domain may also serve as the
binding site for LpL, which contains
positively charged heparin-binding
domains. A key question is how
GPIHBP1 might facilitate interactions
between LpL and chylomicrons. If
GPIHBP1 binds only a single ligand
(either a chylomicron particle or LpL),
then there must be a mechanism
to promote interaction betweenCell MetabolisGPIHBP1-chylomicron and GPIHBP1-
LpL hetero-oligomeric complexes (Fig-
ure 1B). Beigneux and colleagues
(2007) suggest that the GPI-anchored
complexes might cluster in raft do-
mains in the plasma membrane,
thereby bringing LpL into contact with
chylomicrons. Alternatively, GPIHBP1,
which is amember of a class of GPI-an-
chored surface receptors known to ex-
ist as homodimers (Cunningham et al.,
2003), may facilitate interaction through
dimerization (Figure 1C). In either event,
chylomicron-associated triglyceride
would be accessible to LpL, leading to
release of free fatty acids and transport
across the endothelial surface, possibly
through CD36- or FATP-dependent
mechanisms (Schaffer, 2002). Delinea-
tion of the role of the GPIHBP1 acidic
domain in chylomicron and/or LpL
binding and the stoichiometry of the
ligand-receptor interaction awaits future
structure-function and binding stud-
ies. Further insight into these mecha-
nisms may be revealed through the
detection of GPIHBP1 homodimers and
by mapping of amino acid residues
required for homodimer formation.
According to this model, efficient li-
polytic processing of chylomicrons re-
quires binding of lipoprotein particles
to GPIHBP1, which serves as a plat-
form for lipoprotein-LpL interaction.
While the precise nature of the
GPIHBP1-chylomicron interaction is
not yet known, the demonstration by
Beigneux and colleagues (2007) that
GPIHBP1 expression increases apo-AVm 5, April 2007 ª2007 Elsevier Inc. 229
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PreviewsFigure 1. Model for Binding of Chylomicrons and LpL to GPIHBP1 at the Endothelial Cell Surface
(A) GPIHBP1 is tethered to the endothelial cell surface by aGPI anchor and contains an amino-terminal acidic domain that is proposed to be a specific
binding site for both chylomicrons and LpL.
(B) The acidic domain of GPIHBP1 may bind chylomicrons through interaction with positively charged domains of apolipoproteins exposed on the
lipoprotein surface. The acidic domain of GPIHBP1 may also serve as the binding site for LpL, which contains positively charged heparin-binding
domains.
(C) Interaction between GPIHBP1-bound chylomicrons and LpL may involve clustering of the GPI-anchored proteins or homodimerization. Lipolysis
of chylomicron-associated triglycerides liberates free fatty acids (FA), which are transported into endothelial cells.g
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dbinding suggests that this chylomi-
cron-associated, exchangeable apoli-
poprotein might serve as a ligand for
GPIHBP1. Indeed, apo-AV deficiency
is characterized by impaired LpL hy-
drolysis and elevated serum triglycer-
ides (Grosskopf et al., 2005), although
not to the extreme level that occurs in
Gpihbp1/ mice. This implies that
apolipoproteins other than apo-AV
may mediate chylomicron binding. An
intriguing possibility raised by the au-
thors is that GPIHBP1 may serve as
a receptor for apo-B48, the key struc-
tural apolipoprotein in chylomicrons.
The observation that apo-B48 and
chylomicrons are uniquely found in
mammals and that GPIHBP1 is pres-
ent only in mammalian genomes lends
plausibility to this hypothesis. The
processing of apo-B100-containing
lipoproteins (e.g., VLDL) could occur
through interaction of endothelium-
expressed HSPGs with apo-B100
heparin-binding domains, high-affinity
sites that are absent in apo-B48 (Weis-230 Cell Metabolism 5, April 2007 ª2007 Eraber and Rall, 1987). Apo-B48-
ontaining chylomicrons, in contrast
o apo-B100-containing lipoproteins,
ay depend to a greater extent on
PIHBP1 for LpL-mediated lipolysis.
n apo-B48 receptor, therefore, might
rovide an important physiological
dvantage by promoting preferential
rocessing of chylomicron-delivered
ietary triglycerides in GPIHBP1-
xpressing tissues (e.g., heart and ad-
pose tissue). In theory, this could not
nly safeguard the supply of free fatty
cids for cardiac energetics and adi-
ose tissue storage but also channel
o the heart dietary essential fatty
cids, such as n-3 polyunsaturated
atty acids, which are known to have
ntiatherogenic and antiarrhythmic
roperties (Kang and Leaf, 1996).
Several inherited disorders causing
ccumulation of chylomicrons in
lasma have been described in hu-
ans. These chylomicronemia syn-
romes are caused exclusively by
eficiency of either LpL or apoC-II,lsevier Inc.an essential cofactor for LpL (Brunzell
and Deeb, 2001). So far, no cases of
chylomicronemia associated with de-
fective binding of chylomicrons or
LpL to endothelial cells have been de-
scribed. It is possible that homozygous
GPIHBP1 deficiency in humans, unlike
inmice, causes embryonic lethality. Al-
ternatively, other receptorsmight com-
pensate for loss of GPIHBP1 function.
While additional studies are needed to
further define the molecular events in-
volved in chylomicron processing, the
identification of GPIHBP1 as a putative
chylomicron/LpL receptor is an impor-
tant milestone in our understanding of
lipoprotein physiology and offers new
insight into this complex and carefully
choreographed metabolic pathway for
the delivery of lipid nutrients to cells.
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The neuropeptide oxytocin is syn
into the blood and within defined
iors. A recent study of CD38/
transmembrane receptor CD38 i
The neuropeptide oxytocin has at-
tracted intense attention due to the
discovery of its amazing variety of
behavioral functions. Oxytocin and
the related nonapeptide vasopressin
are essential parts of the hypotha-
lamo-neurohypophyseal system. First
described in 1928 by the German biol-
ogist Ernst Scharrer in fish, this clearly
delineated, compact arrangement of
relatively large neurons at the base of
the brain with long axonal projections
to the neurohypophysis and contacts
with blood capillaries has served as
a valuable model system in neuroen-
docrinology and neuroscience. Oxyto-
cin was the first neuropeptide to be
characterized (by Du Vigneaud and, in-
dependently, by Acher in the 1950s).
Studies of oxytocin have provided key
insights into the bursting pacemaker
activity of neurosecretory neurons,
neuropeptidergic pathways and re-
lease patterns within the brain, neuro-
nal-glial interactive plasticity, neuro-
peptide receptor antagonists, and,
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past two decades has illuminated theGoldberg, I.J. (1996). J. Lipid Res. 37, 693–
707.
Grosskopf, I., Baroukh, N., Lee, S.J., Kamari,
Y., Harats, D., Rubin, E.M., Pennacchio, L.A.,
and Cooper, A.D. (2005). Arterioscler. Thromb.
Vasc. Biol. 25, 2573–2579.
Ioka, R.X., Kang, M.J., Kamiyama, S., Kim,
D.H., Magoori, K., Kamataki, A., Ito, Y., Takei,uropeptide of Lo
f Its Secrets
inology, University of Regensburg, 93053 Re
e.uni-regensburg.de
thesized in the brain and released fr
brain regions that regulate emotio
mice (Jin et al., 2007) has demon
n secretion of oxytocin into the blo
molecular and cellular mechanisms of
neuronal oxytocin synthesis, trans-
port, processing, and release, both
into the blood and within the brain
(Landgraf and Neumann, 2004). These
findings have been causally linked to
behavioral and other phenomena in
both animal and human studies (Fig-
ure 1). Brain oxytocin modulates social
behaviors, includingmaternal care and
aggression, pair bonding, sexual be-
havior, social memory and support,
and human trust, and downregulates
stress responses, including anxiety.
Thus, while neuropeptides such as va-
sopressin and CRH might represent
the Homerian sea monsters Scylla
and Charybdis in behavioral regula-
tion, oxytocin, like Circe and Thetis
(who guided Odysseus to avoid both
dangers) would mediate anxiolytic
and prosocial influences, beneficial to
relief, reproduction, and love (Landgraf
et al., 2007). This system is therefore
one of the most promising neuromo-
dulator/neurotransmitter systems of
the brain for psychotherapeutic inter-
vention and treatment of numerous
psychiatric illnesses, for example so-
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A recent article in Nature by Higa-
shida and colleagues (Jin et al., 2007)
sheds a bright light on the molecular
and cellular mechanisms of neuronal
oxytocin release. The authors apply an
impressive variety of molecular, cellu-
lar, neuroendocrine, and behavioral
techniques to convincingly character-
ize the transmembrane receptor CD38
as an essential component in the se-
cretory machinery of oxytocin neu-
rons. CD38 can catalyze the formation
of the secondmessengers cyclic ADP-
ribose (cADPR) and nicotinic acid ade-
nine dinucleotide phosphate (NAADP),
which are essential for the activation of
intracellular Ca2+ stores (Empson and
Galione, 1997). In the presence of
calmodulin, increasing the concentra-
tion of cADPR increases the sensitivity
of Ca2+-induced Ca2+ release (Lee,
2005). Thus, application of cADPR
through a patch-clamp pipette aug-
ments the action-potential-induced,
and ryanodine-sensitive, rise in intra-
cellular Ca2+. These CD38-dependent
cADPR and NAADP signaling
m 5, April 2007 ª2007 Elsevier Inc. 231
